Rehabilitation With HHFNC in COPD in Nocturnal NIV

Chronic Obstructive Pulmonary Disease Clinical Trial

Official title:

Efficacy of Exercise Training With Humified High Flow Nasal Cannula, in Patients With Chronic Obstructive Pulmonary Disease Already in Nocturnal Non-Invasive Ventilation

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04683952
• Other study ID #: FDG_HFNC_COPD_01
• Status: Recruiting
• Phase: N/A
• Start date: January 1, 2020
• Est. completion date: January 2022

Study information

• Verified date: May 2020
• Source: Fondazione Don Carlo Gnocchi Onlus
• Contact: Paolo Banfi, MD
• Phone: 02 40308812
• Email: pabanfi[@]dongnocchi.it
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Humidified High Flow Nasal Cannula (HHFNC), with optional supplemental oxygen delivery, has evolved in recent years with an increasing number of papers that show a better meet with respiratory demand, decrease oxygen dilution, increased Functional Residual Capacity (FRC), dead space washout, more tolerate than Non Invasive Ventilation (NIV) and provide heated and humidified gas. HHFNC is mainly used in intensive care settings or in acute respiratory diseases for the treatment of mild to moderate acute hypoxic respiratory failure and ventilator weaning. The aim of this study is to evaluate, in patients with Chronic Obstructive Pulmonary Disease (COPD) in nocturnal NIV, according to the European Respiratory Society (ERS) and American Thoracic Society (ATS) guidelines, whether HHFNC during rehabilitation has an additional effect in increasing the distance in 6 Minute Walking Distance (6MWD) compared to the control group with nocturnal NIV without HHFNC treatment. As secondary objectives, we expect a decrease in Emergency Department (ED) accesses, General Practitioner (GP) unplanned visits, hospitalizations and an improvement of the quality of life and patient satisfaction.

Description:

RECRUITMENT PHASE: A qualified physiotherapist will check patient lists daily with the aim of identifying suitable candidates for the study.

The patients will be enrolled from January 2020 till june 2021 and they will be stratified individually and randomized by a dedicated software (https://www.randomizer.org/) into two groups:

• Experimental group - Chronic Obstructive Pulmonary Disease (COPD) patients in nocturnal Non Invasive Ventilation (NIV) underwent to respiratory rehabilitation with Humidified High Flow Nasal Cannula (HHFNC) with / without Oxygen Therapy (O2), according to medical prescription;

• Control group - patients in nocturnal NIV underwent to respiratory rehabilitation without HFNC with / without O2, according to medical prescription.

Before randomization, individual clinical inclusion and exclusion criteria will be taken into account in relation to the ability of each patient to tolerate the administration of the high flow ventilation program foreseen by the study.

RUN IN PHASE: After the assessment, each patient will perform a training session prior to the cycle ergometer, during which the subject will work on the workload and the established flow. The intensity of the workload will be 60-80% of the Wmax, calculated with the Hill's formula:

Wmax = ( 0.122 x 6MWD) + (72, 683 x Height) - 117.109

(where 6MWD is the distance walked on the 6-minute walk test, and the patient's height must be expressed in meters).

NIV and HHFNC will be administered through VEMO 150 (EOVE SA. 64000 Pau - France), a device with which it is possible setting up to 4 different ventilation programs. The High Flow can be delivered, as a continuous flow through the humidified nasal cannulas, up to 60 L / min with or without additional oxygen therapy according to medical prescription. The patients of the experimental group will be trained with the most adequate continuous flow, in a range between 20 and 60 L/min, according to the maximum flow supported by the patient.

FOLLOW UP PHASE: Outpatient rehabilitation will be performed in 3 cycles, each cycle in 40-minute sessions, 3 times a week. Each session starts with the cycle ergometer with a 5-minute warm-up to an intensity of 0 watts, continues with a 30-minute resistance training phase at a continuous target intensity (60-80% Wmax), then a warm-down of 5 minutes at an intensity of 0 watts.

The rehabilitation will be followed by a three-month washout period, for 3 cycles.

MEASUREMENTS: We have identified four periods to evaluate gas exchange, Forced expiratory volume in one second (FEV1) and respiratory muscle strength, dyspnea, exercise capacity, the presence of obstructive/central sleep apnea, prediction of mortality, activities of daily life, the impact of the disease and the quality of life.

These four periods are:

• T0: baseline;

• T1: at the end of the first rehabilitation cycle;

• T2: at the end of the second rehabilitation cycle;

• T3: at the end of the third rehabilitation cycle.

At the beginning of the study, demographics and clinical characteristics of eligible study participants will be collected.

Patients will be evaluated for:

• Blood gas analysis (BGA) in T0, T1, T2, T3;

• Spirometry: Forced Vital Capacity (FVC), FEV1 and FEV1/FEVC% in T0, T3;

• Questionnaire of the British Medical Research Council (MRC) modified, in T0, T1, T2, T3;

• Basic / Transition Dyspnea Index (BDI / TDI), in T0, T1, T2, T3;

• 6 Minute Walking Distance (6MWD) with / without oxygen therapy, according to the medical prescription during the effort, in T0, T1, T2, T3;

• COPD Assessment Test (CAT) in T0, T1, T2, T3;

• Night time Polygraph to detect apnea/hypopnea, in T0, T3 ;

• BODE INDEX (where BODE means body mass index, obstruction of air flow, dyspnoea and exercise capacity), in order to estimate the probability of survival, in T0, T1, T2, T3;

• Saint George Respiratory Questionnaire (SGRQ) to investigate the quality of life in T0 and T3;

• Evaluation of the perception of muscle fatigue and dyspnea (Borg RPE) and Visual Analogue Scale (VAS) each session.

During training, and the run-in phase, the physiotherapist will take note of FiO2 and of the dyspnea at the beginning and end of the session through VAS / BORG and again when the patient will be evaluated in 6MWD).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: January 2022
• Est. primary completion date: January 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Diagnosis of Chronic Obstructive Pulmonary Disease (post-bronchodilator Forced Expiratory Volume in 1 second (FEV1) / Forced Vital Capacity (FVC) <0.7) ;

• Nocturnal Non Invasive Ventilation (NIV) prescription according to ATS/ERS guidelines with or without long-term oxygen therapy;

• Clinical stability (no exacerbation and no changing in respiratory drugs in the last 7 days);

Exclusion Criteria:

• Orthopedic or neurological pathologies that limit physical performance;

• Cognitive impairment (Mini-Mental State Examination <24);

• Advanced heart disease, pulmonary fibrosis, participation in other clinical studies in the six months preceding the start of the study.

Related Conditions & MeSH terms

• Chronic Obstructive Pulmonary Disease
• Lung Diseases
• Lung Diseases, Obstructive
• Pulmonary Disease, Chronic Obstructive

Intervention

Device:
• Exercise training with Humified High Flow Nasal Cannula
The experimental group will be trained using HHFNC with the most adequate continuous flow, in a range between 25 and 30 L / min.

Other:
• Exercise training - Control Group
The control group will perform exercise training in spontaneous breathing.

Locations

Country	Name	City	State
Italy	IRCCS Santa Maria Nascente, Fondazione Don Carlo Gnocchi	Milan

Sponsors (1)

Lead Sponsor	Collaborator
Fondazione Don Carlo Gnocchi Onlus

Country where clinical trial is conducted

Italy, 

References & Publications (4)

Ergan B, Oczkowski S, Rochwerg B, Carlucci A, Chatwin M, Clini E, Elliott M, Gonzalez-Bermejo J, Hart N, Lujan M, Nasilowski J, Nava S, Pepin JL, Pisani L, Storre JH, Wijkstra P, Tonia T, Boyd J, Scala R, Windisch W. European Respiratory Society guidelines on long-term home non-invasive ventilation for management of COPD. Eur Respir J. 2019 Sep 28;54(3). pii: 1901003. doi: 10.1183/13993003.01003-2019. Print 2019 Sep. — View Citation

Hill K, Jenkins SC, Cecins N, Philippe DL, Hillman DR, Eastwood PR. Estimating maximum work rate during incremental cycle ergometry testing from six-minute walk distance in patients with chronic obstructive pulmonary disease. Arch Phys Med Rehabil. 2008 Sep;89(9):1782-7. doi: 10.1016/j.apmr.2008.01.020. — View Citation

Schwabbauer N, Berg B, Blumenstock G, Haap M, Hetzel J, Riessen R. Nasal high-flow oxygen therapy in patients with hypoxic respiratory failure: effect on functional and subjective respiratory parameters compared to conventional oxygen therapy and non-invasive ventilation (NIV). BMC Anesthesiol. 2014 Aug 7;14:66. doi: 10.1186/1471-2253-14-66. eCollection 2014. — View Citation

Stéphan F, Bérard L, Rézaiguia-Delclaux S, Amaru P; BiPOP Study Group. High-Flow Nasal Cannula Therapy Versus Intermittent Noninvasive Ventilation in Obese Subjects After Cardiothoracic Surgery. Respir Care. 2017 Sep;62(9):1193-1202. doi: 10.4187/respcare.05473. Epub 2017 Aug 14. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Points at Saint George Respiratory Questionnaire (SGRQ)	The third outcome concerns the quality of life for which we expect changes in the results at the Saint George Respiratory Questionnaire (SGRQ) in the experimental group. SGRQ: from 0 (no health impairment) to 100 (maximum health impairment).	"Baseline ( pre-intervention)" and "Immediately after the intervention".
Primary	Change from baseline in 6MWD	The first outcome we expect to find is a change in the distance at 6-Minute Walking Distance (6MWD).	"Baseline ( pre-intervention)" and "Immediately after the intervention".
Secondary	Number of Exacerbations, GP visits and admission to ED and ICU	The second outcome is change of COPD exacerbation as admission to the Intensive Care Unit (ICU), to the admission to the ED with/without hospitalization, Generale Practitioner (GP) unplanned visits.	Through study completion, an average of 1 year.

External Links

•   The Global Initiative for Chronic Obstructive Lung Disease (GOLD) Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease
•   Who. Chronic respiratory Diseases. WHO's role and activities: COPD
•   Who. Chronic respiratory diseases.Burden of COPD